Westford, Mass. – July 10, 2006 — Dassault Systèmes (DS) (NASDAQ: DASTY; Euronext Paris: #13065, DSY.PA), a world leader in 3D and Product Lifecycle Management (PLM) solutions, today announced the latest updates to the MatrixOne Medical Device Accelerator (MDA). The MatrixOne MDA manages Quality System Regulation (QSR)/ISO-regulated design processes, projects, documents and data, and is the only medical device-tailored solution built on an enterprise-class PLM platform that has been proven effective at the industry’s top three device manufacturers.
Being innovative and responsive in a regulated environment is complex and requires enterprise collaboration, control and coordination. While innovation and change are the lifeblood of successful medical device companies, they often get bogged down in administrative regulation details, losing sight of customer needs along with piling up resource inefficiencies. The MatrixOne MDA is designed to meet the specific needs of medical device manufacturers.
“The MatrixOne Medical Device Accelerator is allowing Possis to better manage the entire product development process,“ said Tim Anderson, director of engineering, Possis Medical. “Giving everyone on a project team access to information – including R&D, quality, engineering, design, marketing, production, regulatory affairs, and senior management – will make Possis a more collaborative and efficient organization.“
The MDA’s features are subdivided into three major groups: Enterprise Design Control, which provides configurable templates and workflows to streamline the product design process; Documentation and Change Control, a central repository for documents and data; and Project and Program Control, enabling a collaborative environment for managing projects, design activities, drive process standards and provide enterprise visibility. Other noteworthy features include:
Leverage Integration to Microsoft Office tools to manage documents “Medical device companies are under increasing pressure to speed time-to-market while needing to meet stringent regulatory demands,” said Barry Foster, medical devices product director for ENOVIA MatrixOne. “We understand the needs of medical device manufacturers and have created a product that will allow them to work in the type of environment that they are used to, while improving innovation, accelerating product development, and meeting federal regulations.”
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 E of the Securities and Exchange Act of 1934, as amended, which reflect Dassault Systemes' current judgment on certain issues. Because such statements apply to future events, they are subject to risk and uncertainties that could cause the actual results to differ materially. Important factors, which could cause actual results to differ materially, are described in the Company's reports on Form 20-F and 6-K on file with the Securities and Exchange Commission.